In the context of multiple sclerosis (MS), ALX/FPR2, GPR32, GPR18, and ChemR23 were differentially expressed on PBMCs according to disease activity, with decreased mRNA levels in patients with progressive MS as compared to patients presenting relapsing or remitting MS (84). This evidence concerns the gene FPR2 and multiple sclerosis.